On August 11, 2026, the Centers for Medicare and Medicaid Services issues a final rule titled, “Prohibition on Federal Medicaid and Children’s Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children” (Final Rule). The Final Rule prohibits payments to State Medicaid plans for “sex-rejecting procedures” for children under 18 or to a separate Children’s Health Insurance Program (CHIP) for children under 19. Among the definitions included in the Final Rule are:

On August 10, 2026, President Trump signed an Executive Order titled, Delivering Gold Standard Childhood Vaccine Recommendations for Americans (the EO). The EO recommends all children get immunizations for 11 diseases, a decrease from the 18 diseases recommended by the Centers for Disease Control and Prevention in 2024. The EO states that immunizations that are no longer recommended for all children are now recommended for shared clinical decision-making.

On July 31, 2026, the Health Resources and Services Administration (HRSA) announced (Notice) a revised 340B Rebate Model Pilot Program (Pilot) that would allow participating drug manufacturers to provide 340B discounts through retrospective rebates.

On July 28, 2026, the Centers for Medicare & Medicaid Services (CMS) announced the Calendar Year (CY) 2027 Part D national average monthly bid amount is $296.05, the Part D base beneficiary premium is $41.33, and the de minimis amount is $2.

On July 2, 2026, the Centers for Medicare and Medicaid Services (CMS) released the CY 2027 Medicare Outpatient Prospective Payment System (OPPS) proposed rule (Proposed Rule).

On June 3, 2026, the Centers for Medicare and Medicaid Services (CMS) released educational materials for the Medicare GLP-1 Bridge program. The Medicare GLP-1 Bridge program will start on July 1, 2026. Through this short-term demonstration, CMS will be expanding access to certain GLP-1 medications to eligible Medicare Part D beneficiaries who do not currently have access to these medications through the Part D benefit.

On June 1, 2026, the Centers for Medicare and Medicaid Services issued an interim final rule (IFR) with comment period to implement provisions in Public Law 119-21 (also known as “H.R. 1” or the "One Big Beautiful Bill Act").

On April 21, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a Status Update on the Medicare GLP-1 BRIDGE Demo and BALANCE Model in Part D for CY 2027.

On April 23, 2026, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to accelerate Medicare coverage for certain FDA-designated Breakthrough Devices by aligning evidence requirements and coverage decisions earlier in development.

• On April 6, 2026, the Centers for Medicare and Medicaid Services (CMS) issued the Calendar Year (CY) 2027 Medicare Advantage (MA) and Part D Rate Announcement (Rate Announcement).

On April 2, 2026, the Centers for Medicare and Medicaid Services (CMS) issued the Contract Year 2027 and Certain Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule. 

On February 23, 2026, the U.S. Food and Drug Administration (FDA) released draft guidance outlining a new regulatory framework to support approval of individualized therapies for ultra-rare diseases when randomized controlled trials are infeasible because of extremely small patient populations.